INTRODUCTION {#s1}
============

Cancer is one of the most common diseases causing considerable morbidity and mortality worldwide. Environmental and genetic factors together contribute to the development of cancers \[[@R1]--[@R4]\]. It has been reported that DNA damage and repair is an important factor in carcinogenesis \[[@R5]--[@R7]\]. *BRCA2* is a well-known cancer susceptibility gene involved in the repair of double-stranded DNA breaks which functions by regulating the intracellular shuttling and activity of RAD51, another critical protein in homologous recombination \[[@R8]--[@R10]\]. Studies have shown that cancer carcinogenesis is related to abnormalities in DNA repair mechanisms partially caused by a change in gene function which can result from genetic polymorphisms \[[@R11], [@R12]\].

Within the last few years, many studies have focused on the association between *BRCA2* gene polymorphisms and cancer risk, including breast cancer, ovarian cancer, non-Hodgkin lymphoma, prostate cancer and others \[[@R13]--[@R18]\]. The rs144848 is the only common non-synonymous polymorphism in exon 10 of the *BRCA2* gene \[[@R19]\]. The change from A to C in the rs144848 polymorphism results in an asparagine-to-histidine transition (N372H) which may affect BRCA2 structure at residues 290-453, a region which has been determined to interact with the histone acetyltransferase P/CAF prior to transcriptional activation of target genes \[[@R20]\]. Over the past decade, many association studies have been conducted to explore the role of the rs144848 N372H polymorphism in cancer risk \[[@R13], [@R15], [@R17], [@R18], [@R21]--[@R40]\], but it is still inconclusive whether this polymorphism in the *BRCA2* gene is associated with susceptibility to cancer. Therefore, we performed a systematic review and meta-analysis of published studies focused on the association between the rs144848 polymorphism and cancer risk. Our in-depth analysis may drive a more precise estimation of risk which could in turn help identify additional genetic targets for future therapeutic interventions.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

A flow diagram for the search strategy is shown in Figure [1](#F1){ref-type="fig"}. Based on the search strategy, 2,174 articles were identified in the initial search. After reading titles and abstracts, 1,788 articles were excluded and 386 articles were reviewed for full text. According to the study inclusion/exclusion criteria, 40 relevant studies from 30 publications including 34,911 cases and 48,329 controls were used for the final meta-analysis \[[@R13]--[@R15], [@R17], [@R18], [@R21], [@R23]--[@R40], [@R46]--[@R52]\]. Nine studies were medium quality and 31 studies were high quality. The main characteristics of these included studies are shown in Table [1](#T1){ref-type="table"}.

![Study flow diagram](oncotarget-08-39818-g001){#F1}

###### Characteristics of included studies that contributed to associations between rs144848 and cancer risk

  Study \[ref\] per SNP             Year   Race/ethnicity   Source^a^   Cases   Controls   Allele frequencies   NOS assessment   Cancer type                                         
  --------------------------------- ------ ---------------- ----------- ------- ---------- -------------------- ---------------- ------------- ------ ------ ----- ------ ------ --- ------------
  Healey et al. \[[@R12]\]          2000   Caucasian        PB          234     116        99                   19               266           138    115    13    0.71   0.73   7   Breast
  Healey et al. \[[@R12]\]          2000   Caucasian        PB          1667    858        664                  145              1201          631    493    77    0.71   0.73   7   Breast
  Healey et al. \[[@R12]\]          2000   Caucasian        PB          450     236        180                  34               228           124    94     10    0.72   0.75   7   Breast
  Healey et al. \[[@R12]\]          2000   Caucasian        PB          659     325        285                  49               866           433    373    60    0.71   0.72   7   Breast
  Healey et al. \[[@R12]\]          2000   Caucasian        PB          449     270        154                  25               453           277    152    24    0.77   0.78   7   Breast
  Spurdle et al. \[[@R45]\]         2002   Caucasian        PB          1397    720        548                  129              775           417    308    50    0.71   0.74   7   Breast
  Ishitobi et al. \[[@R22]\]        2003   Asian            HB          149     97         47                   5                144           85     56     3     0.81   0.78   7   Breast
  Menzel et al. \[[@R24]\]          2004   Caucasian        PB          211     104        91                   16               912           482    361    69    0.71   0.73   7   Breast
  Menzel et al. \[[@R24]\]          2004   Caucasian        PB          94      53         35                   6                152           84     57     11    0.75   0.74   7   Breast
  Cox et al. \[[@R44]\]             2005   Caucasian        Nested      1285    695        501                  89               1660          884    647    129   0.74   0.73   7   Breast
  Millikan et al. \[[@R25]\]        2005   African          PB          762     564        183                  15               675           510    153    12    0.86   0.87   7   Breast
  Millikan et al. \[[@R25]\]        2005   Caucasian        PB          1265    662        521                  82               1135          579    467    89    0.73   0.72   7   Breast
  Garcia-Closas et al. \[[@R21]\]   2006   Caucasian        PB          3161    1617       1278                 266              2701          1412   1057   232   0.71   0.72   7   Breast
  Garcia-Closas et al. \[[@R21]\]   2006   Caucasian        PB          1968    1007       826                  135              2276          1239   897    140   0.72   0.74   7   Breast
  Johnson et al. \[[@R47]\]         2007   Caucasian        NA          473     233        201                  39               2461          1278   993    190   0.71   0.72   6   Breast
  Palli et al. \[[@R48]\]           2007   Caucasian        PB          91      48         31                   12               261           127    107    27    0.70   0.69   6   Breast
  Baynes et al. \[[@R46]\]          2007   Caucasian        PB          4537    2306       1892                 339              4339          2182   1824   333   0.72   0.71   7   Breast
  Seymour et al. \[[@R49]\]         2008   Caucasian        HB          252     127        111                  14               100           50     44     6     0.72   0.72   6   Breast
  Dombernowsky et al. \[[@R19]\]    2009   Caucasian        PB          1200    604        503                  93               4119          2129   1677   313   0.71   0.72   6   Breast
  Juwle et al. \[[@R23]\]           2012   Asian            NA          100     68         28                   4                50            39     8      3     0.82   0.86   6   Breast
  Hasan et al. \[[@R11]\]           2013   African          HB          100     38         33                   29               100           33     32     35    0.55   0.49   6   Breast
  Jumaah et al. \[[@R50]\]          2014   African          NA          36      26         10                   0                10            10     0      0     0.86   1.00   6   Breast
  Auranen et al. \[[@R26]\]         2003   Caucasian        PB          680     355        272                  53               1546          819    629    98    0.72   0.73   7   Ovarian
  Auranen et al. \[[@R26]\]         2003   Caucasian        PB          441     222        176                  43               1097          578    445    74    0.70   0.73   7   Ovarian
  Wenham et al. \[[@R28]\]          2003   Caucasian        PB          312     169        128                  15               398           227    146    25    0.75   0.75   7   Ovarian
  Beesley et al. \[[@R32]\]         2007   Caucasian        PB          492     249        203                  40               948           502    383    63    0.71   0.73   8   Ovarian
  Beesley et al. \[[@R32]\]         2007   Caucasian        PB          930     460        401                  69               825           461    296    68    0.71   0.74   8   Ovarian
  Ramus et al. \[[@R36]\]           2008   Mixed            Nested      4174    2196       1655                 323              7402          3859   2979   564   0.72   0.72   7   Ovarian
  Quaye et al. \[[@R37]\]           2009   Caucasian        PB          1459    779        569                  111              2294          1200   925    169   0.73   0.72   7   Ovarian
  Shen et al. \[[@R30]\]            2006   Mixed            PB          476     250        191                  35               555           301    220    34    0.73   0.74   7   NHL^c^
  Scott et al. \[[@R33]\]           2007   Caucasian        PB          757     387        307                  63               676           375    253    48    0.71   0.74   7   NHL
  Shen et al. \[[@R34]\]            2007   Caucasian        PB          556     271        236                  49               498           246    203    49    0.70   0.70   7   NHL
  Hill et al. \[[@R16]\]            2006   Mixed            PB          1116    577        441                  98               926           505    361    60    0.71   0.74   7   NHL
  Salagovic et al. \[[@R39]\]       2012   Caucasian        HB          107     62         34                   11               127           82     40     5     0.74   0.80   7   NHL
  Hu et al. \[[@R27]\]              2003   Asian            PB          120     69         39                   12               231           126    95     10    0.74   0.75   6   Esophageal
  Wu et al. \[[@R31]\]              2006   Caucasian        PB          604     306        246                  52               595           332    223    40    0.71   0.75   8   Bladder
  Debniak et al. \[[@R35]\]         2008   Caucasian        Nested      627     288        280                  59               3819          1994   1580   245   0.68   0.73   6   Melanoma
  Agalliu et al. \[[@R15]\]         2010   Caucasian        PB          1269    655        498                  116              1243          654    500    89    0.71   0.73   8   Prostate
  Agalliu et al. \[[@R15]\]         2010   African          PB          142     104        36                   2                79            59     18     2     0.86   0.86   8   Prostate
  Kotnis et al. \[[@R38]\]          2012   Asian            HB          109     35         56                   18               186           81     70     35    0.58   0.62   7   Multiple

^a^ Source in control, PB population-based study, HB hospital-based study

^b^ Major allele frequency

^c^ non-Hodgkin lymphoma

Association between *BRCA2* rs144848 polymorphism and cancer risk {#s2_2}
-----------------------------------------------------------------

As shown in Table [2](#T2){ref-type="table"}, there was no heterogeneity in any genetic model. The meta-analysis results showed that there were significant associations between the rs144848 polymorphism and cancer risk in all genetic models (H allele *vs*. N allele, OR = 1.044, 95% CI = 1.021-1.068, *p* \< 0.001; NH *vs*. NN, OR = 1.037, 95% CI = 1.006-1.069, *p* = 0.018; HH *vs*. NN, OR = 1.104, 95% CI = 1.044-1.168, *p* = 0.001; dominant model, OR = 1.047, 95% CI = 1.018-1.078, *p* = 0.002; recessive model, OR = 1.086, 95% CI = 1.028-1.146, *p* = 0.003; Figure [2](#F2){ref-type="fig"}--[6](#F6){ref-type="fig"}).

###### Summary of OR and 95%CI for association between rs144848 polymorphism and susceptibility to cancer

  Variable per SNP       *I*^2^ (%)   *p* for heterogeneity   OR (95% CI)           *p* value    *p* for publication bias   Effects model   Sensitive analysis                                      
  ---------------------- ------------ ----------------------- --------------------- ------------ -------------------------- --------------- -------------------- --------------------- ------------ -------
  H allele vs N allele   7.0          0.345                   1.044 (1.021-1.068)   \<0.001^a^   0.045                      fixed           \[[@R36]\]           1.053 (1.028-1.080)   \<0.001^a^   0.143
  NH vs NN               0.0          0.491                   1.037 (1.006-1.069)   0.018^a^     0.147                      fixed           \[[@R36]\]           1.048 (1.014-1.082)   0.005^a^     0.352
  HH vs NN               16.8         0.183                   1.104 (1.044-1.168)   0.001^a^     0.066                      fixed           \[[@R46]\]           1.125 (1.060-1.194)   \<0.001^a^   0.148
  Dominant model         0.0          0.470                   1.047 (1.018-1.078)   0.002^a^     0.069                      fixed           \[[@R36]\]           1.059 (1.026-1.092)   \<0.001^a^   0.069
  Recessive model        16.8         0.184                   1.086 (1.028-1.146)   0.003^a^     0.114                      fixed           \[[@R46]\]           1.102 (1.040-1.168)   0.001^a^     0.214

^a^ Statistically significant
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Meta-regression analysis {#s2_3}
------------------------

The following covariates were considered for meta-regression: ethnicity, study design and cancer type. The results showed that cancer type contributed to effect in the meta-analysis (H allele *vs*. N allele, *p* = 0.011; HH *vs*. NN, *p* = 0.006; dominant model, *p* = 0.039; recessive model, *p* = 0.011).

Subgroup analysis by cancer type stratification {#s2_4}
-----------------------------------------------

Based on cancer type, four groups were included in the meta-analysis: breast cancer group, ovarian cancer group, non-Hodgkin lymphoma group and other cancers group. The results showed that the rs144848 polymorphism was not associated with breast cancer or ovarian cancer in any model. However, the rs144848 polymorphism was associated with non-Hodgkin lymphoma in four models (H allele *vs*. N allele, OR = 1.110, 95% CI = 1.023-1.205, *p* = 0.012; HH *vs*. NN, OR = 1.263, 95% CI = 1.035-1.542, *p* = 0.022; dominant model, OR = 1.118, 95% CI = 1.008-1.240, *p* = 0.035; recessive model, OR = 1.216, 95% CI = 1.002-1.476, *p* = 0.048) and with other cancers in all genetic models (Table [3](#T3){ref-type="table"}).

###### Summary of OR and 95% CI for association of rs144848 polymorphism with cancer risk by cancer type stratification

  Subgroup               *p* for heterogeneity   *I*^2^ (%)   OR (95% CI)           *p* value    Effects model
  ---------------------- ----------------------- ------------ --------------------- ------------ ---------------
  N allele vs H allele                                                                           
  Breast cancer          0.679                   0.0          1.028 (0.997-1.060)   0.075        fixed
  Ovarian cancer         0.359                   9.1          1.024 (0.981-1.068)   0.280        fixed
  NHL                    0.518                   0.0          1.110 (1.023-1.205)   0.012^a^     fixed
  Others                 0.658                   0.0          1.158 (1.074-1.249)   \<0.001^a^   fixed
  NH vs NN                                                                                       
  Breast cancer          0.890                   0.0          1.029 (0.988-1.072)   0.166        fixed
  Ovarian cancer         0.080                   46.8         1.015 (0.959-1.074)   0.604        fixed
  NHL                    0.954                   0.0          1.090 (0.977-1.215)   0.122        fixed
  Others                 0.090                   47.5         1.117 (1.009-1.236)   0.033^a^     fixed
  HH vs NN                                                                                       
  Breast cancer          0.491                   0.0          1.056 (0.978-1.139)   0.162        fixed
  Ovarian cancer         0.446                   0.0          1.063 (0.957-1.180)   0.253        fixed
  NHL                    0.294                   19.0         1.263 (1.035-1.542)   0.022^a^     fixed
  Others                 0.653                   0.0          1.439 (1.199-1.726)   \<0.001^a^   fixed
  Dominant model                                                                                 
  Breast cancer          0.852                   0.0          1.033 (0.994-1.074)   0.097        fixed
  Ovarian cancer         0.156                   35.7         1.022 (0.969-1.079)   0.420        fixed
  NHL                    0.855                   0.0          1.118 (1.008-1.240)   0.035^a^     fixed
  Others                 0.237                   26.3         1.162 (1.055-1.280)   0.002^a^     fixed
  Recessive model                                                                                
  Breast cancer          0.477                   0.0          1.044 (0.969-1.124)   0.259        fixed
  Ovarian cancer         0.351                   10.3         1.057 (0.954-1.170)   0.290        fixed
  NHL                    0.277                   21.6         1.216 (1.002-1.476)   0.048^a^     fixed
  Others                 0.377                   6.2          1.346 (1.130-1.603)   0.001^a^     fixed

^a^ Statistically significant

Association between *BRCA2* rs144848 polymorphism and breast cancer risk {#s2_5}
------------------------------------------------------------------------

There were 22 breast cancer studies with different ethnicities and study designs. To assess the role of genetic background and the source of the control population in breast cancer risk, we carried out a subgroup analysis. In the analysis of genetic background, the overall population was divided into three subgroups, Caucasian, Asian, and African. The results showed that no statistically significant association was observed in any population (Table [4](#T4){ref-type="table"}). In the analysis of study design, the overall population was divided into two subgroups, population-based studies and hospital-based studies. The results showed that the allele model was associated with the risk of breast cancer based on population-based studies (H allele *vs*. N allele, OR = 1.034, 95% CI = 1.000-1.068, *p* = 0.047; Table [5](#T5){ref-type="table"}).

###### Summary of OR and 95% CI for association of rs144848 polymorphism with breast cancer risk by ethnicity stratification

  Subgroup               *p* for heterogeneity   *I*^2^ (%)   OR (95% CI)           *p* value   Effects model
  ---------------------- ----------------------- ------------ --------------------- ----------- ---------------
  N allele vs H allele                                                                          
  Caucasian              0.690                   0.0          1.029 (0.997-1.061)   0.075       fixed
  Asian                  0.262                   20.5         0.974 (0.692-1.372)   0.882       fixed
  African                0.185                   40.8         1.024 (0.850-1.235)   0.801       fixed
  NH vs NN                                                                                      
  Caucasian              0.970                   0.0          1.028 (0.986-1.072)   0.189       random
  Asian                  0.050                   74.0         1.133 (0.427-3.006)   0.801       random
  African                0.337                   8.1          1.069 (0.798-1.430)   0.656       random
  HH vs NN                                                                                      
  Caucasian              0.332                   10.4         1.060 (0.981-1.146)   0.138       fixed
  Asian                  0.551                   0.0          1.086 (0.377-3.124)   0.879       fixed
  African                0.388                   0.0          0.877 (0.529-1.455)   0.612       fixed
  Dominant model                                                                                
  Caucasian              0.925                   0.0          1.033 (0.993-1.075)   0.106       fixed
  Asian                  0.101                   62.8         0.955 (0.640-1.424)   0.820       fixed
  African                0.244                   29.2         1.065 (0.855-1.325)   0.575       fixed
  Recessive model                                                                               
  Caucasian              0.333                   10.3         1.048 (0.972-1.130)   0.220       fixed
  Asian                  0.395                   0.0          1.078 (0.378-3.072)   0.888       fixed
  African                0.443                   0.0          0.876 (0.548-1.399)   0.579       fixed

###### Summary of OR and 95% CI for association of rs144848 polymorphism with breast cancer risk by the study design stratification

  Subgroup               *p* for heterogeneity   *I*^2^ (%)   OR (95% CI)           *p* value   Effects model
  ---------------------- ----------------------- ------------ --------------------- ----------- ---------------
  H allele vs N allele                                                                          
  PB                     0.691                   0.0          1.034 (1.000-1.068)   0.047^a^    fixed
  HB                     0.759                   0.0          0.883 (0.707-1.103)   0.273       fixed
  Others                 0.264                   24.5         1.011 (0.923-1.108)   0.810       fixed
  NH vs NN                                                                                      
  PB                     0.953                   0.0          1.030 (0.986-1.076)   0.182       fixed
  HB                     0.684                   0.0          0.864 (0.638-1.171)   0.346       fixed
  Others                 0.174                   39.6         1.050 (0.930-1.186)   0.428       fixed
  HH vs NN                                                                                      
  PB                     0.315                   12.4         1.076 (0.991-1.168)   0.082       fixed
  HB                     0.677                   0.0          0.844 (0.501-1.422)   0.525       fixed
  Others                 0.559                   0.0          0.957 (0.763-1.200)   0.702       fixed
  Dominant model                                                                                
  PB                     0.916                   0.0          1.037 (0.995-1.081)   0.085       fixed
  HB                     0.750                   0.0          0.856 (0.642-1.141)   0.290       fixed
  Others                 0.195                   36.2         1.035 (0.922-1.162)   0.558       fixed
  Recessive model                                                                               
  PB                     0.297                   14.0         1.063 (0.982-1.151)   0.132       fixed
  HB                     0.625                   0.0          0.867 (0.538-1.398)   0.558       fixed
  Others                 0.627                   0.0          0.943 (0.757-1.175)   0.600       fixed

^a^ Statistically significant

Sensitivity analysis {#s2_6}
--------------------

To determine the degree to which an individual study affected the overall OR estimates, one-way sensitivity analysis was performed by excluding one study at a time and sequentially recalculating the overall effect. The results showed no influence on pooled ORs and 95% CIs as individual studies were excluded.

Publication bias {#s2_7}
----------------

Publication bias was observed in only one model (H allele *vs*. N allele, *p* = 0.045; Table [2](#T2){ref-type="table"}). However, there was no significant publication bias in any genetic model (*p* \> 0.05) after sensitivity analysis. Trim and fill results showed that the adjusted risk estimate remained significant (H allele *vs*. N allele, OR = 1.028, 95% CI = 1.006-1.050, *p* = 0.014), which confirmed that the results of this meta-analysis were statistically robust.

DISCUSSION {#s3}
==========

The mechanisms underlying carcinogenesis are still not fully clear, but it has been suggested that genetic and environmental factors play the most important role in the development of cancer. The BRCA2 protein can regulate homologous recombination by interacting with the RAD51 recombinase, and many studies have suggested that the rs144848 polymorphism in the *BRCA2* gene is a susceptibility locus for cancers \[[@R8]\]. However, until now, there has been no consistent result regarding the association between the rs144848 N372H polymorphism and cancer risk. To explain these contradictory results, a meta-analysis including 34,911 cases and 48,329 controls was conducted and five genetic models were utilized to assess the association between the *BRCA2* rs144848 polymorphism and the risk of cancer.

In our meta-analysis, the results showed that there was no heterogeneity in any genetic model in overall population, while associations were observed between the rs144848 polymorphism and cancer risk in all genetic models. Meta-regression analysis suggested that ethnicity and study design had no influence on overall effect, but cancer type did contribute to effect (H allele *vs*. N allele, *p* = 0.011; HH *vs*. NN, *p* = 0.006; dominant model, *p* = 0.039; recessive model, *p* = 0.011). Based on cancer type, four groups were included in the meta-analysis: breast cancer group, ovarian cancer group, non-Hodgkin lymphoma group and other cancers group. The results showed that the rs144848 polymorphism was not associated with breast cancer or ovarian cancer in any model. However, the rs144848 polymorphism was associated with non-Hodgkin lymphoma in four models, and associated with other cancers in all genetic models.

The results showed a statistically significant association in all genetic models for overall population. Due to the relatively large number of research studies on breast cancer, we also did a subgroup analysis in the breast cancer group. To assess the role of genetic background in breast cancer, we stratified the population by ethnicity and found no association in Caucasian, Asian, and African subgroups. Considering that the number of publications in Asian and African populations was small, we believe our results may not be reliable due to insufficient statistical power, so additional studies should be conducted to confirm our results. However, after subgroup analysis by study design stratification, we found that the *BRCA2* rs144848 N372H polymorphism was associated with increasing the risk of breast cancer in population-based studies (H allele *vs*. N allele, OR = 1.034, 95% CI = 1.000-1.068, *p* = 0.047). One-way sensitivity analysis suggested no influence of individual studies on pooled ORs and 95% CIs.

In 2006, a study from the breast cancer association consortium summarized the common breast cancer-associated polymorphisms but failed to show a significant association between the *BRCA2* rs144848 polymorphism and breast cancer \[[@R53]\]. In 2010, Qiu *et al*. found in a meta-analysis that the *BRCA2* rs144848 H allele may be a low-penetrant risk factor for developing breast cancer \[[@R54]\]. In 2014, Xue *et al*. conducted a meta-analysis to assess the association between the *BRCA2* rs144848 polymorphism and cancer susceptibility \[[@R55]\]. In contrast to Qiu *et al*., they did not find an association between the *BRCA2* rs144848 polymorphism and breast cancer, but did observe an association with ovarian cancer. Different results from Xue *et al*. were then obtained in 2015 by Wang *et al*., who found that the rs144848 polymorphism was not associated with ovarian cancer. Compared with this latter study, we updated and added several new studies which were strictly filtered by a quality assessment. In addition, we used five genetic models to assess the role of the *BRCA2* rs144848 polymorphism in our meta-analysis. Another important difference from Wang *et al*. was that their results were based on the risk estimates obtained without the original genotype data, whereas all studies included in our meta-analysis provided genotype data, so that our results were more precise by calculating effect directly without potential deviations and biases.

The strength of this meta-analysis is that the most current literature was included. To guarantee the quality of the meta-analysis, the Newcastle-Ottawa scale was conducted to assess the quality of included studies, and a strict procedure for data extraction was performed by two investigators according to inclusion and exclusion criteria. Furthermore, no low-quality literature was included in this meta-analysis which might possibly have influenced our results. One-way sensitivity analysis and meta-regression were also performed to increase the robustness of our conclusions. Subgroup analysis by ethnicity and the source of the control population were used to explain the effect of genetic background and study design.

There are some limitations in this meta-analysis. First, the literature search strategy was limited by language, and only published papers in English were included. Second, because we excluded literature without original data, some studies were excluded. Third, other potential interactions including environment × gene, gene × gene and some potential covariates were not considered due to insufficient information.

In conclusion, our meta-analysis determined that the *BRCA2* rs144848 polymorphism was associated with non-Hodgkin lymphoma, and indicated that the rs144848 H allele of the *BRCA2* gene may be a low-penetrate risk factor enhancing carcinogenesis in breast cancer. Further well-designed studies are warranted to clarify the mechanism and increase comprehensive understanding of the role of the *BRCA2* rs144848 polymorphism in cancer.

MATERIALS AND METHODS {#s4}
=====================

Publication research {#s4_1}
--------------------

Studies were retrieved by searching PubMed, Embase and Google Scholar following the guidelines in Preferred Reporting Items for Systematic Reviews and Meta-Analyses ([PRISMA](#SD1){ref-type="supplementary-material"}) 2009 \[[@R41]\]. The last search was updated on April 2016 with the terms "cancer", "tumor", "BRCA", "polymorphism", "genetic", "variant", "rs144848" and "N372H". References in potential articles were also included in order to find more relevant studies.

Inclusion criteria {#s4_2}
------------------

All articles were reviewed by two investigators independently. Studies were included in the meta-analysis if they met the following criteria: (1) Studies were case-control or cohort studies; (2) articles were original studies of human participants; (3) genotype distributions were available; (4) studies were published in English; and (5) articles were association studies between rs144848 polymorphism and cancer risk. If studies were drawn from the same population, only the study with the largest sample size or with a sufficient quantity of useful data was included. If an article reported the results from different studies, each study was treated as a separate comparison in our meta-analysis.

Quality score assessment {#s4_3}
------------------------

The Newcastle-Ottawa scale was used to assess the quality of studies \[[@R42]\]. Three items including selection, comparability and exposure were used to calculate the score of studies with a maximum score of nine. Any disagreements were adjusted by a third reviewer. A total score of three or lower, four to six and seven or greater was considered to indicate low, medium and high quality studies, respectively.

Data extraction {#s4_4}
---------------

Data were extracted from included studies using a standardized form. For each study, the following information was extracted: (1) name of first author, (2) year of publication, (3) ethnicity of population, (4) source of control population and (5) sample size and genotype distribution. Ethnicity was categorized as Caucasian, Asian or African, and the study design was categorized as population-based study, hospital-based study or nested study.

Statistical analysis {#s4_5}
--------------------

The odds ratios (ORs) with corresponding 95% confidence intervals (95% CIs) were calculated to assess the association between the rs144848 polymorphism and cancer risk. Five models were used in this meta-analysis: (1) H allele *vs*. N allele, (2) NH *vs*. NN, (3) HH *vs*. NN, (4) dominant model, (NH+HH *vs*. NN), and (5) recessive model, (HH *vs*. NH+NN). Statistical analysis was performed using STATA 11.0 (Stata Corporation, College Station, TX, USA). The chi-square test was conducted to evaluate if the studies deviated from Hardy-Weinberg equilibrium, and the threshold for disequilibrium was *p* \< 0.05. Cochran\'s *Q* test and *I*^2^ statistic test were performed to assess heterogeneity across individual studies (*p* \< 0.10 and *I*^2^ \> 50% suggested heterogeneity). The fixed-effects model (the Mantel-Haenszel method) was used to estimate the pooled OR if *I*^2^ \< 50%; otherwise, the random-effects model (the DerSimonian and Laird method) was used \[[@R43]\]. A value of *p* \< 0.05 was accepted as the significance threshold for each genetic model.

Subgroup analysis was conducted based on ethnicity (Caucasian, Asian and African) and study design (population-based and hospital-based). If heterogeneity was present, meta-regression was conducted to explore the source of heterogeneity. One-way sensitivity analysis was used to assess the influence of the individual study set to the pooled ORs by sequential exclusion.

A funnel plot was performed to estimate the potential publication bias using Begg\'s test, in which the standard error of log (OR) was plotted against its log (OR) \[[@R44]\]. Egger\'s liner regression test was also used to evaluate publication bias with quantitative analysis as a supplement to the funnel plot \[[@R45]\]. The trim and fill method was used to adjust pooled ORs and 95% CIs if bias was detected.
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